Skip to content
1887

Microbiology Society logo Microbiology

Volume 171, Issue 2

Linking volatile metabolites from bacterial pathogens to exhaled breath condensate of people with cystic fibrosis Open Access

Abstract

Obtaining sputum samples from people with cystic fibrosis (pwCF) for microbiology has become challenging due to the positive clinical effects of the cystic fibrosis transmembrane conductance regulator modulator therapy, elexacaftor-tezacaftor-ivacaftor (ETI). Although ETI improves lung function and reduces sputum production, recent data shows that bacterial pathogens persist, making continued monitoring of infection important. As an alternative to sputum sampling, this study developed a non-invasive technique called ‘Cough Breath’ (CB) to identify volatile organic compounds (VOCs) in exhaled breath condensate (EBC) and link them to cystic fibrosis (CF) bacterial pathogens using purge and trap GC-MS. The CB culturing approach was able to isolate pathogens from expectorated particulates simultaneously with EBC collection; however, culturing positivity was low, with 6% of samples collected (=47) positive for either or . From EBC, we identified VOCs matching those uniquely produced by (7), (12), (8) and (2); however, the overall detection rate was also low. Expanding to VOCs produced across multiple pathogens identified 30 frequently detected in the EBC of pwCF, including 2,3-pentanedione, propyl pyruvate, oxalic acid diallyl ester, methyl isobutyl ketone, methyl nitrate, 2-propenal, acetonitrile, acetoin and 2,3-butanedione. Comparing isolate volatilomes and EBC samples from the same pwCF enhanced detection rates with key VOCs, such as 2,3-pentanedione (86%) and propyl pyruvate (83%), in isolates. Further investigation showed that VOC production differed across strains and at different growth phases, creating variability that may explain the overall low EBC detection rate. Although this study successfully cultured CF pathogens from cough particulates and matched their unique VOCs in EBC samples, our results indicate that microbial volatiles more generally indicative of infection, such as 2,3-pentanedione, may have the most utility in aiding diagnostics in pwCF on ETI who have reduced sputum production in the clinic.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): cough breath , cystic fibrosis , exhaled breath condensate , pathogens and volatile organic compounds
Funding
This study was supported by the:
  • National Institute of Allergy and Infectious Diseases, National Institute of Health (Award R01AI145925)
    • Principal Award Recipient: RobertA. Quinn
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.001536
2025-02-20
2026-04-18

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/micro/171/2/mic001536.html?itemId=/content/journal/micro/10.1099/mic.0.001536&mimeType=html&fmt=ahah

References

  1. Zang X, Monge ME, Gaul DA, McCarty NA, Stecenko A et al. Early detection of cystic fibrosis acute pulmonary exacerbations by exhaled breath condensate metabolomics. J Proteome Res 2020; 19:144–152 [View Article] [PubMed]
     [Google Scholar]
  2. Mahboubi MA, Carmody LA, Foster BK, Kalikin LM, VanDevanter DR et al. Culture-based and culture-independent bacteriologic analysis of cystic fibrosis respiratory specimens. J Clin Microbiol 2016; 54:613–619 [View Article] [PubMed]
     [Google Scholar]
  3. Goss CH, Burns JL. Exacerbations in cystic fibrosis: 1. epidemiology and pathogenesis. Thorax 2007; 62:360–367 [View Article] [PubMed]
     [Google Scholar]
  4. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011; 24:29–70 [View Article]
     [Google Scholar]
  5. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G et al. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 42:5176–5183 [View Article] [PubMed]
     [Google Scholar]
  6. Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW et al. Lung function and microbiota diversity in cystic fibrosis. Microbiome 2020; 8:1–13 [View Article]
     [Google Scholar]
  7. Zemanick ET, Hoffman LR. Cystic fibrosis: microbiology and host response. Pediatr Clin North Am 2016; 63:617–636 [View Article] [PubMed]
     [Google Scholar]
  8. Fenn D, Abdel-Aziz MI, Brinkman P, Kos R, Neerincx AH et al. Comparison of microbial composition of cough swabs and sputum for pathogen detection in patients with cystic fibrosis. J Cyst Fibros 2022; 21:52–60 [View Article] [PubMed]
     [Google Scholar]
  9. Seidler D, Griffin M, Nymon A, Koeppen K, Ashare A. Throat swabs and sputum culture as predictors of P. aeruginosa or S. aureus lung colonization in adult cystic fibrosis patients. PLoS One 2016; 11:e0164232 [View Article] [PubMed]
     [Google Scholar]
  10. Lu J, Carmody LA, Opron K, Simon RH, Kalikin LM et al. Parallel analysis of cystic fibrosis sputum and saliva reveals overlapping communities and an opportunity for sample decontamination. mSystems 2020; 5: [View Article]
     [Google Scholar]
  11. Schultz A, Caudri D. Cough swabs less useful but induced sputum very useful in symptomatic older children with cystic fibrosis. Lancet Respir Med 2018; 6:410–411 [View Article] [PubMed]
     [Google Scholar]
  12. Sosinski LM, H CM, Neugebauer KA, Ghuneim LAJ, Guzior DV et al. A restructuring of microbiome niche space is associated with elexacaftor-tezacaftor-ivacaftor therapy in the cystic fibrosis lung. J Cyst Fibros 2022; 21:996–1005 [View Article] [PubMed]
     [Google Scholar]
  13. Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA et al. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial. Am J Respir Crit Care Med 2022; 205:529–539 [View Article] [PubMed]
     [Google Scholar]
  14. Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F et al. Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Heal Eur 2023; 32:100690 [View Article]
     [Google Scholar]
  15. Nichols DP, Morgan SJ, Skalland M, Vo AT, Van Dalfsen JM et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest 2023; 133:e167957 [View Article] [PubMed]
     [Google Scholar]
  16. Schaupp L, Addante A, Völler M, Fentker K, Kuppe A et al. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J 2023; 62:2202153 [View Article] [PubMed]
     [Google Scholar]
  17. Kos R, Neerincx AH, Fenn DW, Brinkman P, Lub R et al. Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients. Pharmacol Res Perspect 2022; 10:e01015 [View Article] [PubMed]
     [Google Scholar]
  18. Martin C, Guzior DV, Gonzalez CT, Okros M, Mielke J et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after elexacaftor-tezacaftor-ivacaftor therapy. Res Sq 2023rs.3.rs-3356170 [View Article] [PubMed]
     [Google Scholar]
  19. Tunney MM, Wark P. Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist. Eur Respir J 2023; 62:2301008 [View Article] [PubMed]
     [Google Scholar]
  20. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28:321–328 [View Article] [PubMed]
     [Google Scholar]
  21. Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, Szefler SJ et al. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc 2015; 12:221–229 [View Article]
     [Google Scholar]
  22. Ahmed B, Bush A, Davies JC. How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis. Arch Dis Child Educ Pract Ed 2014; 99:181–187 [View Article]
     [Google Scholar]
  23. Kos R, Brinkman P, Neerincx AH, Paff T, Gerritsen MG et al. Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients. J Cyst Fibros 2022; 21:e28–e34 [View Article] [PubMed]
     [Google Scholar]
  24. Kramer R, Sauer-Heilborn A, Welte T, Guzman CA, Höfle MG et al. A rapid method for breath analysis in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2015; 34:745–751 [View Article]
     [Google Scholar]
  25. Neerincx AH, Geurts BP, van Loon J, Tiemes V, Jansen JJ et al. Detection of Staphylococcus aureus in cystic fibrosis patients using breath VOC profiles. J Breath Res 2016; 10:046014 [View Article] [PubMed]
     [Google Scholar]
  26. Bos LDJ, Meinardi S, Blake D, Whiteson K. Bacteria in the airways of patients with cystic fibrosis are genetically capable of producing VOCs in breath. J Breath Res 2016; 10:047103 [View Article] [PubMed]
     [Google Scholar]
  27. Gaisl T, Bregy L, Stebler N, Gaugg MT, Bruderer T et al. Real-time exhaled breath analysis in patients with cystic fibrosis and controls. J Breath Res 2018; 12:036013 [View Article] [PubMed]
     [Google Scholar]
  28. van Aerde KJ, Leegstraten A, van den Kieboom CH, Merkus P, Sintnicolaas C et al. Non-invasive diagnostics of pathogenic bacteria using a breath sampler in children with cystic fibrosis. J Breath Res 2022; 16:046005 [View Article] [PubMed]
     [Google Scholar]
  29. Boots AW, Bos LD, van der Schee MP, van Schooten F-J, Sterk PJ. Exhaled molecular fingerprinting in diagnosis and monitoring: validating volatile promises. Trends Mol Med 2015; 21:633–644 [View Article] [PubMed]
     [Google Scholar]
  30. Horváth I, Barnes PJ, Loukides S, Sterk PJ, Högman M et al. A european respiratory society technical standard: exhaled biomarkers in lung disease. Eur Respir J 2017; 49:1600965 [View Article] [PubMed]
     [Google Scholar]
  31. Ghosh C, Leon A, Koshy S, Aloum O, Al-Jabawi Y et al. Breath-based diagnosis of infectious diseases: a review of the current landscape. Clin Lab Med 2021; 41:185–202 [View Article] [PubMed]
     [Google Scholar]
  32. Lechner M, Fille M, Hausdorfer J, Dierich MP, Rieder J. Diagnosis of bacteria in vitro by mass spectrometric fingerprinting: a pilot study. Curr Microbiol 2005; 51:267–269 [View Article] [PubMed]
     [Google Scholar]
  33. Nizio KD, Perrault KA, Troobnikoff AN, Ueland M, Shoma S et al. In vitro volatile organic compound profiling using GC×GC-TOFMS to differentiate bacteria associated with lung infections: a proof-of-concept study. J Breath Res 2016; 10:026008 [View Article] [PubMed]
     [Google Scholar]
  34. Tsou P-H, Lin Z-L, Pan Y-C, Yang H-C, Chang C-J et al. Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancer. Cancers 2021; 13:1–14 [View Article] [PubMed]
     [Google Scholar]
  35. Wang P, Huang Q, Meng S, Mu T, Liu Z et al. Identification of lung cancer breath biomarkers based on perioperative breathomics testing: a prospective observational study. EClinicalMedicine 2022; 47:101384 [View Article] [PubMed]
     [Google Scholar]
  36. Zou Y, Hu Y, Jiang Z, Chen Y, Zhou Y et al. Exhaled metabolic markers and relevant dysregulated pathways of lung cancer: a pilot study. Ann Med 2022; 54:790–802 [View Article] [PubMed]
     [Google Scholar]
  37. Jia Z, Thavasi V, Venkatesan T, Lee P. Breath analysis for lung cancer early detection—a clinical study. Metabolites 2023; 13:1197 [View Article] [PubMed]
     [Google Scholar]
  38. Bean HD, Rees CA, Hill JE. Comparative analysis of the volatile metabolomes of Pseudomonas aeruginosa clinical isolates. J Breath Res 2016; 10:047102 [View Article] [PubMed]
     [Google Scholar]
  39. Jenkins CL, Bean HD. Current limitations of staph infection diagnostics, and the role of VOCs in achieving culture-independent detection. Pathogens 2023; 12:181 [View Article] [PubMed]
     [Google Scholar]
  40. Davis TJ, Karanjia AV, Bhebhe CN, West SB, Richardson M et al. Pseudomonas aeruginosa volatilome characteristics and adaptations in chronic cystic fibrosis lung infections. Sphere 20205 [View Article]
     [Google Scholar]
  41. Davis MD, Montpetit AJ. Exhaled breath condensate: an update. Immunol Allergy Clin North Am 2018; 38:667–678 [View Article] [PubMed]
     [Google Scholar]
  42. Hunt J. Exhaled breath condensate: an overview. Immunol Allergy Clin North Am 2007; 27:587–596 [View Article] [PubMed]
     [Google Scholar]
  43. van Mastrigt E, de Jongste JC, Pijnenburg MW. The analysis of volatile organic compounds in exhaled breath and biomarkers in exhaled breath condensate in children - clinical tools or scientific toys?. Clin Exp Allergy 2015; 45:1170–1188 [View Article] [PubMed]
     [Google Scholar]
  44. Guzior DV, Okros M, Shivel M, Armwald B, Bridges C et al. Bile salt hydrolase acyltransferase activity expands bile acid diversity. Nature 2024; 626:852–858 [View Article]
     [Google Scholar]
  45. Fitzgerald S, Holland L, Morrin A. An investigation of stability and species and strain-level specificity in bacterial volatilomes. Front Microbiol 2021; 12: [View Article]
     [Google Scholar]
  46. Zhou C, Fey PD. The acid response network of Staphylococcus aureus. Curr Opin Microbiol 2020; 55:67–73 [View Article] [PubMed]
     [Google Scholar]
  47. O’Hara M, Mayhew CA. A preliminary comparison of volatile organic compounds in the headspace of cultures of Staphylococcus aureus grown in nutrient, dextrose and brain heart bovine broths measured using a proton transfer reaction mass spectrometer. J Breath Res 2009; 3:027001 [View Article] [PubMed]
     [Google Scholar]
  48. Chippendale TWE, Gilchrist FJ, Španěl P, Alcock A, Lenney W et al. Quantification by SIFT-MS of volatile compounds emitted by in vitro cultures of S. aureus, S. pneumoniae, and H. influenzae isolated from patients with respiratory diseases. Anal Methods 2014; 6:2460 [View Article]
     [Google Scholar]
  49. Whiteson KL, Meinardi S, Lim YW, Schmieder R, Maughan H et al. Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active PH neutral 2,3-butanedione fermentation. ISME J 2014; 8:1247–1258 [View Article] [PubMed]
     [Google Scholar]
  50. Purcaro G, Nasir M, Franchina FA, Rees CA, Aliyeva M et al. Breath metabolome of mice infected with Pseudomonas aeruginosa. Metabolomics 2019; 15:10 [View Article] [PubMed]
     [Google Scholar]
  51. Scott-Thomas AJ, Syhre M, Pattemore PK, Epton M, Laing R et al. 2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung. BMC Pulm Med 2010; 10:56 [View Article] [PubMed]
     [Google Scholar]
  52. Gilchrist FJ, Belcher J, Jones AM, Smith D, Smyth AR et al. Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis. ERJ Open Res 2015; 1:00044–02015 [View Article] [PubMed]
     [Google Scholar]
  53. Nasir M, Bean HD, Smolinska A, Rees CA, Zemanick ET et al. Volatile molecules from bronchoalveolar lavage fluid can "rule-in" Pseudomonas aeruginosa and "rule-out" Staphylococcus aureus infections in cystic fibrosis patients. Sci Rep 2018; 8:826 [View Article] [PubMed]
     [Google Scholar]
  54. Zhu J, Bean HD, Kuo YM, Hill JE. Fast detection of volatile organic compounds from bacterial cultures by secondary electrospray ionization-mass spectrometry. J Clin Microbiol 2010; 48:4426–4431 [View Article] [PubMed]
     [Google Scholar]
  55. Mustafina M, Silantyev A, Krasovskiy S, Chernyak A, Naumenko Z et al. Identification of exhaled metabolites correlated with respiratory function and clinical features in adult patients with cystic fibrosis by real-time proton mass spectrometry. Biomolecules 2024; 14:1189 [View Article] [PubMed]
     [Google Scholar]
  56. Stewart GG. The production of secondary metabolites with flavour potential during brewing and distilling wort fermentations. Fermentation 2017; 3:63 [View Article]
     [Google Scholar]
  57. Krogerus K, Gibson BR. Influence of valine and other amino acids on total diacetyl and 2,3-pentanedione levels during fermentation of brewer’s wort. Appl Microbiol Biotechnol 2013; 97:6919–6930 [View Article] [PubMed]
     [Google Scholar]
  58. Freschi L, Vincent AT, Jeukens J, Emond-Rheault JG, Kukavica-Ibrulj I et al. The Pseudomonas aeruginosa pan-genome provides new insights on its population structure, horizontal gene transfer, and pathogenicity. Genome Biol Evol 2019; 11:109–120 [View Article] [PubMed]
     [Google Scholar]
  59. Jenkins CL, Bean HD. Dependence of the staphylococcal volatilome composition on microbial nutrition. Metabolites 2020; 10:347 [View Article] [PubMed]
     [Google Scholar]
/content/journal/micro/10.1099/mic.0.001536
Loading
Linking volatile metabolites from bacterial pathogens to exhaled breath condensate of people with cystic fibrosis
Microbiology 171, 001536 (2025); https://doi.org/10.1099/mic.0.001536
/content/journal/micro/10.1099/mic.0.001536
/content/journal/micro/10.1099/mic.0.001536
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error